Rhodesain is the main cysteine protease of , the parasite causing the acute lethal form of Human African Trypanosomiasis. Starting from the dipeptide nitrile , the further introduction of a fluorine atom in the position of the phenyl ring spanning in the P3 site and the switch of the P2 leucine with a phenylalanine led to , a synthetic inhibitor that shows a nanomolar binding affinity towards rhodesain ( = 27 nM) and an improved target selectivity with respect to the parent dipeptide nitrile . In the present work, following the Chou and Talalay method, we carried out a combination study of with curcumin, a nutraceutical obtained from Starting from an affected fraction (f) of rhodesain inhibition of 0.5 (i.e., the IC), we observed an initial moderate synergistic action, which became a synergism for f values ranging from 0.6 to 0.7 (i.e., 60-70% inhibition of the trypanosomal protease). Interestingly, at 80-90% inhibition of rhodesain proteolytic activity, we observed a strong synergism, resulting in 100% enzyme inhibition. Overall, in addition to the improved target selectivity of with respect to , the combination of + curcumin resulted in an increased synergistic action with respect to + curcumin, thus suggesting that it is desirable to use and curcumin in combination.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218348 | PMC |
http://dx.doi.org/10.3390/ijms24108477 | DOI Listing |
BMJ Open
December 2024
Shanghai Health Development Research Center, Shanghai Medical Information Center, Shanghai, China
Objectives: To analyse the impacts of multiple rounds of National Centralised Drug Procurement Policy (NCDP) and National Drug Price Negotiation Policy (NDPN) on the utilisation, expenditure and daily cost of novel hypoglycaemic drugs.
Design: The drug procurement data were obtained from the Shanghai Medical Procurement Agency between January 2016 and December 2022. We examined changes in volume, expenditure of overall hypoglycaemic drugs by descriptive analysis.
Lancet
September 2024
Gustave Roussy Institute, Paris-Saclay University, Paris, France.
Background: [Lu]Lu-PSMA-617 (Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer.
Methods: In this phase 3, randomised, controlled trial conducted at 74 sites across Europe and North America, taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who had progressed once on a previous ARPI were randomly allocated (1:1) to open-label, intravenous Lu-PSMA-617 at a dosage of 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles, or a change of ARPI (to abiraterone or enzalutamide, administered orally on a continuous basis per product labelling).
Lancet Oncol
May 2024
Monash University Eastern Health Clinical School, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia.
Background: Enzalutamide and lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data suggesting complementary benefit if targeted concurrently. In this study, we assessed the activity and safety of enzalutamide plus adaptive-dosed [Lu]Lu-PSMA-617 versus enzalutamide alone as first-line treatment for metastatic castration-resistant prostate cancer.
View Article and Find Full Text PDFLancet Oncol
May 2024
Département de Médecine Nucléaire, Institut du Cancer de Montpellier and Université de Montpellier, Montpellier, France.
Chem Biodivers
December 2023
Organic Chemistry Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune, 411008, India.
As COVID-19 infection caused severe public health concerns recently, the development of novel antivirals has become the need of the hour. Main protease (M ) has been an attractive target for antiviral drugs since it plays a vital role in polyprotein processing and virus maturation. Herein we report the discovery of a novel class of inhibitors against the SARS-CoV-2, bearing histidine α-nitrile motif embedded on a simple dipeptide framework.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!